The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in cooperation with the Association of International Pharmaceutical Manufacturers (AIPM) has recently organised an international scientific and regulatory conference “Biotherapeutic medicines: regulatory challenges and current practices - approaches for harmonization is the first international expert meeting of its kind to take place at Moscow in Russia”. The aim of the conference was to enhance regulation of biotherapeutic medicines.

Generic and innovative drug segments in CIS countries have played a huge role in supporting the pharmaceutical industry. Meanwhile, the effects of programmes such as Russia’s Pharma 2020, Kazakhstan’s GMP initiative and Ukraine’s updated reimbursement structure are visible in the marketplace.

ChemRar Ventures has entered into scouting agreement with Sanofi for a venture investment in Russia and Asia.

The Russian delegation took part in the world largest event for professionals of the biotechnology industry, the BIO International Convention 2013.

Eisai Co., Ltd. announced that it has established a new pharmaceutical sales subsidiary in Moscow, Russia, which will be named Limited Liability Company Eisai ("Eisai Russia"). Eisai Russia will function as a direct subsidiary of Eisai's U.K. pharmaceutical operation, Eisai Europe Ltd.